ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00723736
Recruitment Status : Completed
First Posted : July 29, 2008
Results First Posted : August 6, 2009
Last Update Posted : April 30, 2015
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

July 25, 2008
July 29, 2008
June 18, 2009
August 6, 2009
April 30, 2015
December 2007
June 2008   (Final data collection date for primary outcome measure)
Proportion of Patients With Adverse Events [ Time Frame: Follow-up visit at 3 - 5 weeks after treatment initiation ]
An adverse event is any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, whether or not considered related to the use of that product. This includes the onset of new illness and the exacerbation of pre-existing conditions.
Adverse Events [ Time Frame: Follow-up visit a few weeks after treatment initiation ]
Complete list of historical versions of study NCT00723736 on ClinicalTrials.gov Archive Site
Not Provided
Joint Parent/Child Global Therapeutic Response [ Time Frame: Follow-up visit a few weeks after treatment initiation ]
Not Provided
Not Provided
 
Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)
Non-Interventional Study of the Safe Use of Aerius in Pediatric Patients With Allergic Rhinitis or Chronic Idiopathic Urticaria.
The objective of this non-interventional study is to evaluate the safety of Aerius syrup in pediatric patients aged 1-5 years old with allergic rhinitis or chronic idiopathic uticaria. The patients will receive 2.5 ml (1.25 mg) once daily.
Pediatric patients aged 1-5 years
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Pediatric clinics around Hungary.
  • Rhinitis
  • Urticaria
Drug: Desloratadine
2.5 ml (1.25 mg) once daily
Other Names:
  • Aerius
  • SCH 034117
Pediatric Patients
Those with allergic rhinitis or chronic idiopathic urticaria.
Intervention: Drug: Desloratadine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Same as current
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with allergic rhinitis or chronic idiopathic urticaria
  • Aged 1-5 years old
  • Caregiver's consent to participate

Exclusion Criteria:

  • Healthy individuals
  • Younger or older than the 1-5 year old age range
Sexes Eligible for Study: All
1 Year to 5 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00723736
P04446
No
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
April 2015